Brief Title
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
Official Title
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
Brief Summary
The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction
of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy
(PSP), a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and
cholinergic systems, in particular in the Meynert basalis nucleus. This could participate in
the occurrence of the distractibility in these patients. The aim of this study is to evaluate
the effect of the donepezil, an anticholinesterase, on the distractibility in PSP patients,
by using oculomotor and neuropsychological assessments.
Study Phase
Phase 2
Study Type
Interventional
Condition
Supranuclear Palsy, Progressive
Intervention
donepezil
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
16
Eligibility Criteria
Inclusion Criteria:
- Patients with PSP
- Age > 30 years old
- Disease duration < 5 years
- Mini mental state (MMS) > 24
- Antisaccades %: 40-80%
Exclusion Criteria:
- Other parkinsonian syndromes
- MMS < 24
Gender
All
Ages
30 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
Bertrand Gaymard, MD, PhD, 33-142162218, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT00139373
Organization ID
RBM0323
Study Sponsor
Groupe Hospitalier Pitie-Salpetriere
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Study Sponsor
Bertrand Gaymard, MD, PhD, Principal Investigator, INSERM-U679
Verification Date
July 2005